CV Therapeutics, Inc.
CV Therapeutics, Inc. is a biopharmaceutical company focused primarily on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. The Company applies advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. It promotes Ranexa (ranolazine extended-release tablets), a small molecule drug that inhibits the late sodium current at therapeutic levels and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. In addition to its marketed products, the Company is developing other drug candidates, including regadenoson, a selective application to application (A2A)-adenosine receptor agonist, for potential use as a pharmacologic agent in myocardial perfusion imaging studies.
查看其它语言版本
新闻
周五亚洲各股市在交易时段波动较大，收市涨跌互见。日本日经225指数攀升1.5%，韩国Kospi指数涨0.8%，中国沪市成分指数下跌1.8%，香港恒生指数跌0.7%。在美国政府将持有花旗集团大额股份的消息出台后，周一东京股市下跌逾3%，韩国股市也受市场日益加深的对金融市场的担忧以及韩元疲软的影响，今天开盘走低。
###
50,254 公司背景浏览
- 本页浏览人次: (过去7日: 7) (过去30日: 65) (自发布以来: 9370)
